September 2009 Volume 6 Number 9
Visit Nature Reviews Clinical Oncology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=27&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Clinical Oncology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=71&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=53&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
*********************************************************************
Nature Reviews Clinical Oncology Impact Factor: 9.113*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
AACR Conference:
Advances in Breast Cancer Research: Genetics, Biology and Clinical
Applications
October 13-16, 2009 - San Diego, CA
Carlos L. Arteaga, Lewis A. Chodosh, and Kornelia Polyak, Chairpersons
Presenting discoveries in genetics, cell biology, and molecular biology
relevant to breast cancer development and progression. Please visit:
http://links.ealert.nature.com/ctt?kn=40&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Find this Table of Contents e-alert useful?
Sign up for the monthly alert from Nature Reviews Endocrinology and keep
up-to-date with the latest developments in the field of endocrinology.
Ensure you never miss a crucial article:
http://links.ealert.nature.com/ctt?kn=75&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
2008 impact factor: 6.702*
*2008 Journal Citation Reports, (Thomson Reuters, 2009) Nature Reviews
Endocrinology was previously published as Nature Clinical Practice
Endocrinology & Metabolism.
=====================================================================
----------------------
EDITORIAL
----------------------
We have met the enemy and he is us!
Vincent T. DeVita Jr
p493 | doi:10.1038/nrclinonc.2009.89
http://links.ealert.nature.com/ctt?kn=22&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Hematology: Bortezomib enhances chemotherapy effects in ABC DLBCL
p495 | doi:10.1038/nrclinonc.2009.121
http://links.ealert.nature.com/ctt?kn=25&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Genetics: PARP inhibitor has antitumor activity
p496 | doi:10.1038/nrclinonc.2009.118
http://links.ealert.nature.com/ctt?kn=8&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Improved survival for SCRLM
p496 | doi:10.1038/nrclinonc.2009.124
http://links.ealert.nature.com/ctt?kn=10&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Genetics: Predicting outcomes in patients with neuroblastoma
p497 | doi:10.1038/nrclinonc.2009.119
http://links.ealert.nature.com/ctt?kn=14&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Diagnosis: High metastatic EGFR-survival predictor
p497 | doi:10.1038/nrclinonc.2009.120
http://links.ealert.nature.com/ctt?kn=94&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
HIFU for prostate cancer
p497 | doi:10.1038/nrclinonc.2009.122
http://links.ealert.nature.com/ctt?kn=97&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Immunotherapy: Recurrence-free survival versus quality of life-where do
we draw the line?
p498 | doi:10.1038/nrclinonc.2009.117
http://links.ealert.nature.com/ctt?kn=87&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Pediatric oncology: Aggressive treatment of osteosarcoma improves
health-related quality of life
p498 | doi:10.1038/nrclinonc.2009.123
http://links.ealert.nature.com/ctt?kn=90&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Targeted therapies: Cetuximab plus chemotherapy in patients with advanced
NSCLC
Kakil Ibrahim Rasul and David J. Kerr
p499 | doi:10.1038/nrclinonc.2009.108
Targeting EGFR in patients with non-small-cell lung cancer (NSCLC) in
addition to chemotherapy might provide survival benefits in patients
with EGFR-positive tumors. Indeed, results from the FLEX trial demonstrate
that cetuximab in combination with platinum-based chemotherapy is a new
treatment strategy for patients with advanced NSCLC.
http://links.ealert.nature.com/ctt?kn=91&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Hematology: ESAs to treat anemia-balancing the risks and benefits
John Glaspy
p500 | doi:10.1038/nrclinonc.2009.126
Erythropoiesis-stimulating agents are widely used in patients with cancer;
however, uncertainty persists over their effect on survival. This article
discusses the results of a meta-analysis of randomized, controlled trials
of these agents in patients with cancer.
http://links.ealert.nature.com/ctt?kn=7&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Hematology: Azacitidine improves survival in myelodysplastic syndromes
Michal G. Rose
p502 | doi:10.1038/nrclinonc.2009.125
In the past, myelodysplastic syndromes were managed primarily by supportive
care measures, which had limited effects on symptomatic cytopenias or
on the rate of leukemic transformation of these disorders. A new study
reports that administration of the hypomethylation agent azacitidine
significantly increases overall survival in patients with high-risk
myelodysplastic syndromes compared with conventional care.
http://links.ealert.nature.com/ctt?kn=3&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Immunotherapy: Can we include vaccines with stem-cell transplantation?
John Barrett and Katayoun Rezvani
p503 | doi:10.1038/nrclinonc.2009.115
Peptide vaccines to PRI, WT1, and BCR-ABL have shown promising results
in early trials of patients with leukemia. We discuss vaccine strategies
that have been developed against leukemia, and the potential of a vaccine
and stem-cell transplant combination for the cure of patients with leukemia.
http://links.ealert.nature.com/ctt?kn=5&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Targeted therapies: Role of sorafenib in HCC patients with compromised
liver function
Massimo Di Maio, Bruno Daniele and Francesco Perrone
p505 | doi:10.1038/nrclinonc.2009.114
Sorafenib is the standard treatment for patients with advanced
hepatocellular carcinoma who are not eligible for locoregional therapy.
Although significant improvement in overall survival has been demonstrated
in patients with Child-Pugh A cirrhosis, information is lacking on the
benefits, if any, in patients with compromised liver function and
Child-Pugh B or C cirrhosis.
http://links.ealert.nature.com/ctt?kn=17&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Article series: Antiangiogenic Clinical Strategies
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Axel Grothey and Evanthia Galanis
Published online: 28 July 2009
p507 | doi:10.1038/nrclinonc.2009.110
Bevacizumab has improved survival outcomes in patients with various solid
tumors when combined with chemotherapy. The authors discuss the rationale
for using bevacizumab and other large-molecule agents that target the VEGF
system, and the unanswered questions regarding the use of bevacizumab in
the adjuvant setting. The challenges and opportunities in developing new
strategies and understanding molecular mechanisms are highlighted.
Abstract: http://links.ealert.nature.com/ctt?kn=67&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=34&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno, Sabine Tejpar, Floriana Morgillo, Antonella De Luca,
Eric Van Cutsem and Fortunato Ciardiello
Published online: 28 July 2009
p519 | doi:10.1038/nrclinonc.2009.111
Cetuximab and panitumumab have been approved for the treatment of
metastatic colorectal cancer when used alone or in combination with
irinotecan. Although EGFR is expressed in most metastatic colorectal
tumors, only a subset of patients derive clinical benefit from treatment
with EGFR inhibitors. The experimental and clinical evidence supporting
the use of KRAS testing for selecting patients for treatment with
anti-EGFR monoclonal antibodies is discussed.
Abstract: http://links.ealert.nature.com/ctt?kn=48&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=30&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Yohann Loriot, Pierre Mordant, Eric Deutsch, Ken Andre Olaussen and
Jean-Charles Soria
Published online: 14 July 2009
p528 | doi:10.1038/nrclinonc.2009.106
KRAS mutations can be predictive of resistance to anti-EGFR
monoclonal-based therapy in patients with colorectal cancer. Only limited
studies, however, have assessed the predictive value of KRAS mutations
in response to conventional chemotherapy. In this Review, the authors
assess the available literature and propose that KRAS mutations have
no value in response prediction to conventional chemotherapy in
colorectal cancer, non-small-cell cancer and other solid tumors.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=29&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Imatinib and beyond-exploring the full potential of targeted therapy
for CML
Alfonso Quintas-Cardama, Hagop Kantarjian and Jorge Cortes
Published online: 04 August 2009
p535 | doi:10.1038/nrclinonc.2009.112
Imatinib is the standard frontline therapy for patients with chronic
myeloid leukemia (CML); however, a substantial number require alternative
therapy owing to imatinib intolerance or imatinib resistance. Studies
have shown that second-generation tyrosine kinase inhibitors are
efficacious in restoring cytogenetic responses in patients who require
subsequent therapy. Quintas-Cardama et al. discuss the second-generation
and third-generation targeted agents that have restored cytogenetic
response in patients unresponsive to imatinib, and the strategies being
explored to improve the long-term outcome.
Abstract: http://links.ealert.nature.com/ctt?kn=50&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=35&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Neoadjuvant polychemotherapy in locally advanced Merkel cell
carcinoma
Thomas Jouary, Nathalie Lalanne, Fran�ois Siberchicot, Anne-Sophie Ricard,
Julie Versapuech, Sebastien Lepreux, Michele Delaunay and Alain Taieb
p544 | doi:10.1038/nrclinonc.2009.109
This case study discusses two patients with locally advanced Merkel cell
carcinoma. The authors describe how neoadjuvant polychemotherapy was used
to treat these patients allowing curative-intent surgery plus radiotherapy.
Abstract: http://links.ealert.nature.com/ctt?kn=54&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=43&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Controlling the cost of innovative cancer therapeutics
Nafees N. Malik
p550 | doi:10.1038/nrclinonc.2009.113
The costs associated with innovative cancer therapeutics are excessive,
placing a barrier between drug discovery and healthcare. The article
discusses several strategies that might be effective in reducing the
escalating costs and their impact on innovative cancer drug discovery.
Abstract: http://links.ealert.nature.com/ctt?kn=56&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=46&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Visit the Nature Reviews Clinical Oncology website:
- Advanced online publication
- Search across related content from nature.com
- Web feeds (RSS)
- Downloadable PowerPoint slides of figures and supplementary information
- Links to the European School of Oncology, including e-grandrounds.
http://links.ealert.nature.com/ctt?kn=80&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=52&m=33936916&r=MTc2NDg2OTc4MQS2&b=2&j=NTcyNDkyODgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
